Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Inventory (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Inventory for 16 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 21.09% to $18.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.8 million through Dec 2025, down 21.09% year-over-year, with the annual reading at $18.8 million for FY2025, 21.09% down from the prior year.
  • Inventory for Q4 2025 was $18.8 million at Anika Therapeutics, up from $16.3 million in the prior quarter.
  • The five-year high for Inventory was $51.5 million in Q2 2024, with the low at $16.3 million in Q3 2025.
  • Average Inventory over 5 years is $34.7 million, with a median of $36.6 million recorded in 2021.
  • The sharpest move saw Inventory grew 20.8% in 2024, then tumbled 67.12% in 2025.
  • Over 5 years, Inventory stood at $36.0 million in 2021, then rose by 10.43% to $39.8 million in 2022, then tumbled by 38.57% to $24.4 million in 2023, then fell by 2.53% to $23.8 million in 2024, then fell by 21.09% to $18.8 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $18.8 million, $16.3 million, and $16.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.